Clinical variations of polypoidal choroidal vasculopathy: A cohort study from Japan and the USA.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Choroid Diseases*/drug therapy ; Retinal Drusen*/pathology ; Polyps*/diagnosis ; Polyps*/epidemiology ; Polyps*/pathology ; Choroidal Neovascularization*/diagnosis ; Choroidal Neovascularization*/epidemiology ; Choroidal Neovascularization*/drug therapy; Humans ; Choroid/blood supply ; Cohort Studies ; Retrospective Studies ; Polypoidal Choroidal Vasculopathy ; Japan/epidemiology ; Fluorescein Angiography ; Tomography, Optical Coherence

We describe the clinical characteristics of treatment-naïve polypoidal choroidal vasculopathy (PCV) in three tertiary clinic settings in 2 cities (Chicago in the USA and Nishinomiya in Japan). This cohort study was a retrospective, multicenter, consecutive case series. A total of 126 patients with treatment-naïve PCV-46 in Chicago and 80 in Nishinomiya-were identified. The proportion of PCV in patients with neovascular age-related macular degeneration was lower in Chicago (10.8% vs. 36.9%). Patients in Chicago had a significantly higher prevalence of soft drusen (50.0% vs 25.0%, p = 0.006) and intra-retinal cyst (37.0% vs 15.0%, p = 0.008), and a significantly lower prevalence of pachyvessels (41.3% vs 62.5%, p = 0.03). At baseline, presenting vision for patients in Chicago was worse than in Nishinomiya (mean log MAR: 0.609 vs. 0.312, p < 0.001). Ninety-five eyes were followed for more than one year. The Nishinomiya group received a higher rate of combination therapy (61.0%) compared to the Chicago group (5.3%). Vision and central foveal thickness at month 12 were significantly improved from baseline in both Chicago (p = 0.009 and p = 0.01) and Nishinomiya groups (both p < 0.001). Our study highlights interesting differences in the proportion of PCV, clinical findings and treatment responses of PCV, that need to be further evaluated in larger, epidemiologic cohorts.
(© 2023. The Author(s).)

Br J Ophthalmol. 2017 Oct;101(10):1377-1380. (PMID: 28270486)
Retina. 2019 Oct;39(10):1995-2003. (PMID: 30024574)
Am J Ophthalmol. 2012 Dec;154(6 Suppl):S53-62.e1. (PMID: 23158224)
Ophthalmology. 2021 Sep;128(9):1325-1336. (PMID: 33711380)
Arch Ophthalmol. 2001 Oct;119(10):1417-36. (PMID: 11594942)
Arch Ophthalmol. 1997 Apr;115(4):478-85. (PMID: 9109756)
Ophthalmology. 2015 Sep;122(9):1854-65. (PMID: 26081444)
Sci Rep. 2019 Apr 3;9(1):5565. (PMID: 30944393)
Br J Ophthalmol. 2014 Nov;98(11):1528-33. (PMID: 24997181)
Graefes Arch Clin Exp Ophthalmol. 2021 Feb;259(2):351-361. (PMID: 32812132)
Retina. 2020 Jul;40(7):1403-1411. (PMID: 31181038)
Jpn J Ophthalmol. 2004 Jan-Feb;48(1):37-43. (PMID: 14767649)
Retina. 2016 Dec;36 Suppl 1:S73-S82. (PMID: 28005665)
JAMA Ophthalmol. 2018 Jul 1;136(7):786-793. (PMID: 29801063)
Circulation. 2005 Jun 28;111(25):3481-8. (PMID: 15983262)
Ophthalmol Retina. 2019 Sep;3(9):744-752. (PMID: 31511169)
Retina. 2015 Jan;35(1):1-9. (PMID: 25158945)
Ophthalmology. 2021 Mar;128(3):443-452. (PMID: 32795496)
Stroke. 2009 Jun;40(6):2068-72. (PMID: 19359645)
Am J Ophthalmol. 2022 Feb;234:108-116. (PMID: 34450112)
Ophthalmology. 2001 Apr;108(4):697-704. (PMID: 11297486)
Ophthalmol Retina. 2021 Oct;5(10):945-953. (PMID: 33866022)
Ophthalmology. 2011 May;118(5):846-52. (PMID: 21146223)
Retina. 2018 Dec;38(12):2363-2371. (PMID: 29059101)
Health Serv Res. 2004 Oct;39(5):1429-48. (PMID: 15333116)
Acta Ophthalmol. 2021 Aug;99(5):e706-e714. (PMID: 33289345)
Acta Ophthalmol. 2010 Jun;88(4):e107-14. (PMID: 20337601)
Invest Ophthalmol Vis Sci. 2015 May;56(5):3187-95. (PMID: 26024102)
Retina. 2016 Jan;36(1):1-8. (PMID: 26414957)
Eye (Lond). 2019 Jan;33(1):14-33. (PMID: 29995841)
Adv Ther. 2020 May;37(5):2184-2198. (PMID: 32222903)
Ophthalmology. 2010 May;117(5):928-38. (PMID: 20132989)
Lancet Glob Health. 2014 Feb;2(2):e106-16. (PMID: 25104651)
Arch Ophthalmol. 1999 Nov;117(11):1503-10. (PMID: 10565519)
Arch Ophthalmol. 1999 Aug;117(8):1035-42. (PMID: 10448746)
Retina. 2018 Apr;38(4):708-716. (PMID: 28505013)
Int Sch Res Notices. 2014 Oct 15;2014:527831. (PMID: 27379302)
Ophthalmology. 1999 May;106(5):904-9. (PMID: 10328388)
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2075-85. (PMID: 25619667)
N Engl J Med. 2008 Jun 12;358(24):2606-17. (PMID: 18550876)
Ophthalmol Retina. 2019 Dec;3(12):1016-1025. (PMID: 31606329)
Prog Retin Eye Res. 2016 Jul;53:107-139. (PMID: 27094371)
Ophthalmology. 2014 Aug;121(8):1598-603. (PMID: 24661862)
Am J Ophthalmol. 2014 Aug;158(2):309-318.e2. (PMID: 24844973)

R01 EY019951 United States EY NEI NIH HHS

Date Created: 20230324 Date Completed: 20230327 Latest Revision: 20231217

20250114

PMC10036559

10.1038/s41598-023-31649-x

36959460